“The approval of GAMMAGARD LIQUID ERC reinforces our commitment to supporting individualized treatment approaches for people with primary immunodeficiency, including a therapeutic option that has the ...

SAN ANTONIO — Cutaquig provided safe and effective dosing flexibility for patients with primary immunodeficiency disease, according to data presented at the American Academy of Allergy, Asthma & ...

Neurologist Susan W. Lee, DO, answers common questions about this treatment option for myasthenia gravis. Intravenous immunoglobulin (IVIG) is a pooled collection of antibodies derived from donors’ ...

Intravenous immunoglobulin (IVIG) therapy involves infusing patients with naturally occurring IgG antibodies to treat ...

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment trials ...

KORU Medical’s FREEDOM Syringe Infusion System enables, simplifies, and enhances the delivery of large-volume subcutaneous drugs. Supporting drug products with various requirements for viscosity, flow ...

February 9, 2010 — Low-dose intravenous immunoglobulin (IVIG) reduces pain and improves autonomic limb symptoms in patients with long-standing, refractory complex regional pain syndrome (CRPS), a ...

ARLINGTON, Texas--(BUSINESS WIRE)--AOM Infusion, a leading provider of specialty infusion therapy, announced today that it has been selected by GC Biopharma as a limited distribution partner for ...

For the last eight years, Leslie MacGregor from Newton, Massachusetts, has been getting intravenous infusions every month. The treatment is called immunoglobulin, and it bolsters her defective immune ...

GC Biopharma USA, Inc., a leader in plasma-derived products, announced today its support of data analysis and publication of the 2025 Immunoglobulin National Society (IgNS) Patient 360 Longitudinal ...

TEANECK, N.J., July 16, 2025 /PRNewswire/ -- GC Biopharma USA, Inc., a leader in plasma-derived products, announced the presentation of new data on the viscosity of several commercially available 10% ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...